TCA
HZNP

Troluce Capital Advisors’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Troluce Capital Advisors’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-25,002
Closed -$2.89M – 63
2023
Q3 		$2.89M Buy
+25,002
New +$2.69M 1.09% 27

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $247M AUM 21.93% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Troluce Capital Advisors's HZNP Position: Q4 2023 in Review

Troluce Capital Advisors sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 25,002 shares — an estimated $2.89M sold.

Troluce Capital Advisors first reported a position in HZNP in Q3 2023 and held it in 1 quarter. The position peaked at $2.89M in Q3 2023. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • Troluce Capital Advisors reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • Troluce Capital Advisors sold 25,002 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $2.89M.
  • Troluce Capital Advisors first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2023 and held it in 1 quarter.
  • Troluce Capital Advisors's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $2.89M in Q3 2023.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Troluce Capital Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.